Biotechnology

Biomea Fusion

Biomea Fusion Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Biomea Fusion executive purchases 30,000 shares of company stock

Biomea Fusion to participate in the BIO International Convention 2026

Biomea Fusion's Food Effect Study (COVALENT-121) is expected to be completed by the end of December 2025.

Biomea Fusion expects to announce initial clinical data for its next-generation oral GLP-1 receptor agonist, BMF-650, in the first half of 2026.

D. Boral Capital maintains a Buy rating on Biomea Fusion but lowers the price target to $12 from $16.

Biomea Fusion expects to initiate two key Phase II clinical trials in Q1 2026

D. Boral Capital maintains Buy rating on Biomea Fusion but lowers price target to $12

Biomea Fusion expects to complete the food effect study (COVALENT-121) for icovamenib in December 2025

D. Boral Capital maintains Buy rating on Biomea Fusion, but lowers price target to $12.

H.C. Wainwright Maintains Buy Rating on Biomea Fusion

Biomea Fusion expects to initiate patient enrollment for two Phase II clinical trials in the first quarter of 2026

D. Boral Capital lowers Biomea Fusion's price target to $12 but maintains a Buy rating.

Biomea Fusion Interim CEO purchases 100,000 shares of company stock

Biomea Fusion will present long-term data for its diabetes drug icovamenib in an oral presentation at the WCIRDC conference

Biomea Fusion presented positive preclinical data for BMF-650 at ObesityWeek 2025

Biomea Fusion to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference.

Biomea Fusion's Interim CEO Purchases 100,000 Shares of Company Stock

Biomea Fusion Receives Consensus Recommendation of "Moderate Buy" from Brokerages

D. Boral Capital Maintains Buy Rating on Biomea Fusion, but Lowers Price Target to $12

Mega Fortune

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Andersen

Inspirato

Medline Inc.

Creative Global Tech

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap